Federal investigators don't throw around terms like ninety-three million dollars lightly. When the United States Department of Health and Human Services Office of Inspector General places someone on its fugitive list, it usually signals a massive financial breakdown in public healthcare oversight. Enter Khadeer Khan Mohammed, a 46-year-old lab owner whose operations in Texas triggered an international manhunt stretching all the way to Hyderabad, India.
If you've been following major healthcare fraud cases, the mechanics here might sound grimly familiar. Yet the sheer velocity of the payouts makes this specific file stand out. Let's break down who Khadeer Khan Mohammed is, what federal prosecutors allege he did, and why this case has captured global attention. For another look, read: this related article.
Who Is Khadeer Khan Mohammed
Born on July 5, 1980, Khadeer Khan Mohammed is an Indian-origin businessman who operated American Premier Labs LLC, a clinical testing facility based in Richardson, Texas. Standing roughly five feet ten inches tall and weighing about 170 pounds, Mohammed suddenly transitioned from a local corporate owner to an international fugitive after federal prosecutors unsealed indictments against him in the Northern District of Texas.
US authorities believe Mohammed fled the country and is currently residing in Hyderabad. The Department of Health and Human Services and the FBI have listed him among their prominent targets, urging anyone with tips to contact specialized federal fraud hotlines. Further coverage on this matter has been provided by The Guardian.
The Anatomy of a Ninety-Three Million Dollar Scheme
Healthcare fraud in the United States often targets specialized diagnostics. In Mohammed's case, the primary vehicle for the alleged scam was genetic testing.
Between August 2023 and October 2024, American Premier Labs allegedly submitted roughly $93 million in claims to Medicare. Government healthcare programs are bound by strict statutory rules regarding which diagnostic procedures qualify for reimbursement. Prosecutors state that a massive portion of the tests submitted by Mohammed's lab were entirely ineligible, lacked proper medical authorization, and were never actually utilized in patient care.
The numbers involved stagger the imagination. Out of the $93 million billed, Medicare systems ultimately paid out at least $65 million. To understand how fast money moved through this pipeline, consider one single ten-day window in 2023 when Medicare disbursed approximately $13 million for claims tied to the lab.
How Physicians Were Unwittingly Pulled In
A laboratory cannot simply bill Medicare without a doctor's signature or National Provider Identifier. This creates a major bottleneck for fraudulent operations, which investigators claim Mohammed bypassed through identity theft.
Federal indictments allege that American Premier Labs used real physicians' personal identifying information without their consent. The doctors whose names appeared on the paperwork had no professional relationship with the beneficiaries, never ordered the genetic tests, and often had no idea their credentials were being weaponized to legitimize multi-million-dollar billing cycles. This practice left medical professionals scrambling to clear their names while exposing deep vulnerabilities in how diagnostic billing is validated.
Asset Seizures and the Global Manhunt
Law enforcement agencies don't just issue arrest warrants; they chase cash. Federal investigators have already seized nearly $6 million from various bank accounts allegedly controlled by Mohammed.
Because Mohammed is believed to be hiding out in India, bringing him to trial involves complex international legal frameworks, extradition treaties, and diplomatic channels. Indian authorities and US federal agencies remain locked in coordination regarding his potential location in Hyderabad.
Remember that an indictment contains mere allegations. Under American law, Mohammed remains legally innocent until proven guilty in a court of law. Even so, the sheer scale of the frozen assets and the active fugitive status mean this case will likely remain a focal point for federal healthcare investigators for years to come.
